Context Therapeutics has entered into a license agreement amendment with BioAtla for CT-202. The terms of the amendment reportedly involve a payment by Context Therapeutics, although details of the agreement are not entirely clear. It is suggested that the amendment may make certain antibody licenses perpetual and royalty-free, but the specifics of the arrangement have not been fully disclosed.